Rituximab

Eruptive Squamous Cell Carcinomas Following Treatment With Fludarabine
Eruptive squamous cell carcinoma
by NEXT STEPS IN DERM TEAM on
JDD authors Mihir Shah MD, Jenna Wald MD, and C. William Hanke MD MPH present a case of a patient with eruptive squamous cell carcinomas following treatment with Fludarabine to highlight not only the risk of cSCC in CLL patients and the increased risk for atypical cutaneous malignancies after treatment with systemic therapies such as fludarabine, but also to discuss treatment options for this …

Continue reading "Eruptive Squamous Cell Carcinomas Following Treatment With Fludarabine"

Biologics and Immunomodulators for Immunobullous Diseases
Immunobullous Diseases
by Nishad Sathe, MD on
At ODAC 2023, we had the opportunity to learn about the latest in treatments for blistering diseases from Dr. Karl Saardi, Associate Professor and Director of Inpatient Dermatology at George Washington University. We focused on the pemphigus and pemphigoid group of diseases, which we will review and summarize here. Pemphigus The pemphigus group of diseases is characterized by intraepidermal auto …

Continue reading "Biologics and Immunomodulators for Immunobullous Diseases"

Rituximab Therapeutic Cheat Sheet
Rituximab
by Emily Murphy, MD on
Rituximab was the first monoclonal antibody approved for cancer treatment and now in dermatology, this medication has been life-altering for patients with the severe, autoimmune blistering disease, pemphigus vulgaris. We continue our series, Therapeutic Cheat Sheet, with a closer look at rituximab, which is FDA-approved for the treatment of pemphigus vulgaris, and is also used off label for other …

Continue reading "Rituximab Therapeutic Cheat Sheet"

JDD August 2023 Issue Highlights | Special Focus: Psoriasis
psoriasis
by NEXT STEPS IN DERM TEAM on
With a special focus on the topic of psoriasis, check out highlights from the August issue of the Journal of Drugs in Dermatology (JDD) straight from the JDD Editor’s desk: Consensus Statements on the Use of Corticosteroid-Containing Topical Medications in Psoriasis delves into the expert guidance provided by the Psoriasis Expert Group (PEG), encompassing nine crucial statements that offer com …

Continue reading "JDD August 2023 Issue Highlights | Special Focus: Psoriasis"

Rituximab-Induced Alopecia Universalis in a Patient With Bullous Pemphigoid
by NEXT STEPS IN DERM TEAM on
Alopecia areata is a CD8+ T-lymphocyte driven autoimmune disorder leading to reversible hair loss. While most commonly presenting as isolated well-demarcated non-cicatricial alopecic patches on the scalp, subtypes of alopecia areata include alopecia totalis with loss of all scalp hair and alopecia universalis with complete loss of all body hair. Although primarily an idiopathic condition, several …

Continue reading "Rituximab-Induced Alopecia Universalis in a Patient With Bullous Pemphigoid"